Concepts (137)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Hyperplasia | 12 | 2008 | 54 | 0.860 |
Why?
|
| Finasteride | 9 | 2008 | 12 | 0.620 |
Why?
|
| Prostatic Neoplasms | 12 | 2012 | 441 | 0.590 |
Why?
|
| Enzyme Inhibitors | 8 | 2008 | 162 | 0.560 |
Why?
|
| Doxazosin | 4 | 2008 | 6 | 0.350 |
Why?
|
| Prostate | 6 | 2012 | 68 | 0.340 |
Why?
|
| Prostatectomy | 6 | 2007 | 79 | 0.280 |
Why?
|
| Adrenergic alpha-Antagonists | 3 | 2008 | 27 | 0.280 |
Why?
|
| Disease Progression | 7 | 2007 | 572 | 0.130 |
Why?
|
| Biopsy | 3 | 2012 | 241 | 0.130 |
Why?
|
| Male | 24 | 2012 | 17815 | 0.130 |
Why?
|
| Urinary Retention | 2 | 2004 | 6 | 0.120 |
Why?
|
| Middle Aged | 16 | 2008 | 10834 | 0.110 |
Why?
|
| Humans | 25 | 2012 | 29123 | 0.100 |
Why?
|
| DNA Fingerprinting | 1 | 2011 | 7 | 0.100 |
Why?
|
| Specimen Handling | 1 | 2011 | 31 | 0.100 |
Why?
|
| Medical Errors | 1 | 2011 | 36 | 0.100 |
Why?
|
| Drug Therapy, Combination | 3 | 2008 | 273 | 0.090 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2005 | 248 | 0.090 |
Why?
|
| Aged | 12 | 2008 | 9492 | 0.080 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 2007 | 3 | 0.080 |
Why?
|
| Receptors, Cell Surface | 1 | 2007 | 72 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2012 | 464 | 0.070 |
Why?
|
| Cholestenone 5 alpha-Reductase | 1 | 2005 | 2 | 0.070 |
Why?
|
| Double-Blind Method | 2 | 2004 | 503 | 0.070 |
Why?
|
| alpha-Macroglobulins | 1 | 2005 | 4 | 0.070 |
Why?
|
| Receptors, Adrenergic, alpha-1 | 1 | 2004 | 8 | 0.060 |
Why?
|
| Androgen Antagonists | 1 | 2004 | 15 | 0.060 |
Why?
|
| Predictive Value of Tests | 4 | 2012 | 787 | 0.060 |
Why?
|
| Adenocarcinoma | 1 | 2007 | 301 | 0.060 |
Why?
|
| Prognosis | 5 | 2012 | 1362 | 0.060 |
Why?
|
| Vascular Neoplasms | 1 | 2004 | 14 | 0.060 |
Why?
|
| Penile Implantation | 1 | 2003 | 6 | 0.060 |
Why?
|
| Gene Expression | 1 | 2005 | 332 | 0.060 |
Why?
|
| Hospitals, Teaching | 1 | 2003 | 28 | 0.060 |
Why?
|
| Hospitals, Veterans | 1 | 2003 | 33 | 0.060 |
Why?
|
| Receptors, Virus | 1 | 2003 | 15 | 0.060 |
Why?
|
| Urogenital Neoplasms | 1 | 2003 | 6 | 0.060 |
Why?
|
| Adenoviridae | 1 | 2003 | 61 | 0.060 |
Why?
|
| Gene Transfer Techniques | 1 | 2003 | 69 | 0.060 |
Why?
|
| Analysis of Variance | 1 | 2003 | 454 | 0.050 |
Why?
|
| Urinary Bladder Neck Obstruction | 1 | 2002 | 6 | 0.050 |
Why?
|
| ras GTPase-Activating Proteins | 1 | 2002 | 4 | 0.050 |
Why?
|
| GTPase-Activating Proteins | 1 | 2002 | 6 | 0.050 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2002 | 12 | 0.050 |
Why?
|
| Cell Division | 1 | 2002 | 97 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2002 | 90 | 0.050 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2003 | 249 | 0.050 |
Why?
|
| DNA-Binding Proteins | 1 | 2002 | 142 | 0.050 |
Why?
|
| Research Design | 1 | 2003 | 286 | 0.050 |
Why?
|
| Promoter Regions, Genetic | 1 | 2002 | 212 | 0.050 |
Why?
|
| DNA Methylation | 1 | 2002 | 130 | 0.050 |
Why?
|
| Proteins | 1 | 2002 | 140 | 0.050 |
Why?
|
| Prostate-Specific Antigen | 3 | 2007 | 61 | 0.050 |
Why?
|
| Severity of Illness Index | 1 | 2003 | 863 | 0.050 |
Why?
|
| Treatment Outcome | 5 | 2007 | 3101 | 0.050 |
Why?
|
| Neoplasm Staging | 3 | 2005 | 436 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2002 | 337 | 0.040 |
Why?
|
| Follow-Up Studies | 3 | 2007 | 2109 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 2 | 2007 | 189 | 0.030 |
Why?
|
| Adult | 5 | 2004 | 8426 | 0.030 |
Why?
|
| Survival Rate | 2 | 2007 | 795 | 0.030 |
Why?
|
| RNA, Messenger | 2 | 2005 | 514 | 0.030 |
Why?
|
| False Negative Reactions | 1 | 2012 | 21 | 0.030 |
Why?
|
| Acute Disease | 2 | 2004 | 239 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2012 | 122 | 0.030 |
Why?
|
| Immunohistochemistry | 2 | 2005 | 519 | 0.030 |
Why?
|
| Azasteroids | 1 | 2011 | 1 | 0.030 |
Why?
|
| Time Factors | 2 | 2008 | 2001 | 0.020 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 1 | 2007 | 6 | 0.020 |
Why?
|
| Age Distribution | 1 | 2007 | 198 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2007 | 281 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2012 | 1306 | 0.020 |
Why?
|
| Placebo Effect | 1 | 2006 | 14 | 0.020 |
Why?
|
| Urination Disorders | 1 | 2006 | 5 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2007 | 199 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2008 | 347 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2007 | 525 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2007 | 532 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2005 | 35 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2005 | 35 | 0.020 |
Why?
|
| Culture Media, Conditioned | 1 | 2005 | 52 | 0.020 |
Why?
|
| Tissue Culture Techniques | 1 | 2005 | 40 | 0.020 |
Why?
|
| Stromal Cells | 1 | 2005 | 70 | 0.020 |
Why?
|
| Flutamide | 1 | 2004 | 5 | 0.020 |
Why?
|
| Leuprolide | 1 | 2004 | 8 | 0.020 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2004 | 35 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2007 | 859 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2003 | 3719 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2005 | 281 | 0.020 |
Why?
|
| Life Tables | 1 | 2003 | 4 | 0.020 |
Why?
|
| Texas | 1 | 2003 | 35 | 0.010 |
Why?
|
| Equipment Failure | 1 | 2003 | 22 | 0.010 |
Why?
|
| Prosthesis-Related Infections | 1 | 2003 | 23 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2004 | 274 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2005 | 298 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2005 | 320 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 2004 | 156 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 2003 | 76 | 0.010 |
Why?
|
| Sexual Dysfunctions, Psychological | 1 | 2003 | 8 | 0.010 |
Why?
|
| Placebos | 1 | 2003 | 61 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2007 | 1688 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2005 | 799 | 0.010 |
Why?
|
| Reoperation | 1 | 2003 | 203 | 0.010 |
Why?
|
| Erectile Dysfunction | 1 | 2003 | 48 | 0.010 |
Why?
|
| Data Collection | 1 | 2003 | 163 | 0.010 |
Why?
|
| Mice, Nude | 1 | 2003 | 276 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2004 | 637 | 0.010 |
Why?
|
| Area Under Curve | 1 | 2002 | 85 | 0.010 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2002 | 4 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2002 | 33 | 0.010 |
Why?
|
| COS Cells | 1 | 2002 | 28 | 0.010 |
Why?
|
| ROC Curve | 1 | 2002 | 149 | 0.010 |
Why?
|
| DNA Primers | 1 | 2002 | 87 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2002 | 73 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2002 | 74 | 0.010 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2002 | 33 | 0.010 |
Why?
|
| History, 20th Century | 1 | 2002 | 68 | 0.010 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2002 | 36 | 0.010 |
Why?
|
| Comorbidity | 1 | 2003 | 540 | 0.010 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2002 | 65 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2002 | 158 | 0.010 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2002 | 57 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2002 | 172 | 0.010 |
Why?
|
| Base Sequence | 1 | 2002 | 240 | 0.010 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2002 | 72 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2002 | 280 | 0.010 |
Why?
|
| Patient Selection | 1 | 2003 | 257 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2002 | 350 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2003 | 681 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2003 | 721 | 0.010 |
Why?
|
| Clinical Competence | 1 | 2003 | 307 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2005 | 546 | 0.010 |
Why?
|
| Animals | 2 | 2003 | 7299 | 0.010 |
Why?
|
| Incidence | 1 | 2004 | 1119 | 0.010 |
Why?
|
| Mice | 1 | 2003 | 2370 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2003 | 3112 | 0.010 |
Why?
|